Search tips
Search criteria 


Logo of jmedgeneJournal of Medical GeneticsVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Med Genet. 1997 January; 34(1): 63–72.
PMCID: PMC1050849

Preparing for presymptomatic DNA testing for early onset Alzheimer's disease/cerebral haemorrhage and hereditary Pick disease.


The acceptability of presymptomatic testing in 21 people at 50% risk for the APP-692 mutation causing presenile Alzheimer's disease or cerebral haemorrhage resulting from cerebral amyloid angiopathy (FAD-CH), and in 43 people at 50% risk for hereditary Pick disease (HPD) was assessed. Neither group differed in demographic variables. Thirty-nine people (64%) in the whole group would request presymptomatic testing if it were clinically available, although two-thirds did not yet feel ready to take it. The most important reasons in the HPD and FAD-CH group for taking the test were: to further basic research (42% and 47%, respectively), informing children (47% and 50%, respectively), future planning (29% and 47%, respectively), and relieving uncertainty (46% and 27%, respectively). The most commonly cited effect of an unfavourable test result concerned increasing problems for spouses (75% and 76%, respectively) and children (61% and 57%, respectively). Most respondents denied that an unfavourable result would have adverse effects on personal mood or relationship. One-third of all respondents favoured prenatal testing where one of the parents had an increased risk for HPD or FAD-CH. Participants would encourage their offspring to have the test before starting a relationship (35%) and before family planning (44%). Thirty-seven percent of the respondents would encourage their children to opt for prenatal diagnosis. People at risk for HPD were significantly more preoccupied with the occurrence of potential symptoms in themselves, compared with those at risk for FAD-CH, reflecting the devastating impact that disinhibition in the affected patient has on the family. Our findings underline the need for adequate counselling and the availability of professional and community resources to deal with the impact of test results in subjects and their relatives.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.9M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Gispert S, Twells R, Orozco G, Brice A, Weber J, Heredero L, Scheufler K, Riley B, Allotey R, Nothers C, et al. Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat Genet. 1993 Jul;4(3):295–299. [PubMed]
  • Haan J, Hardy JA, Roos RA. Hereditary cerebral hemorrhage with amyloidosis--Dutch type: its importance for Alzheimer research. Trends Neurosci. 1991 Jun;14(6):231–234. [PubMed]
  • Mullan M, Crawford F, Buchanan J. Technical feasibility of genetic testing for Alzheimer's disease. Alzheimer Dis Assoc Disord. 1994;8(2):102–115. [PubMed]
  • Buxton J, Shelbourne P, Davies J, Jones C, Van Tongeren T, Aslanidis C, de Jong P, Jansen G, Anvret M, Riley B, et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature. 1992 Feb 6;355(6360):547–548. [PubMed]
  • Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995 Jun 29;375(6534):754–760. [PubMed]
  • Hoogeveen AT, Willemsen R, Meyer N, de Rooij KE, Roos RA, van Ommen GJ, Galjaard H. Characterization and localization of the Huntington disease gene product. Hum Mol Genet. 1993 Dec;2(12):2069–2073. [PubMed]
  • Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Martin JJ, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet. 1992 Jun;1(3):218–221. [PubMed]
  • Heston LL, Mastri AR. Age at onset of Pick's and Alzheimer's dementia: implications for diagnosis and research. J Gerontol. 1982 Jul;37(4):422–424. [PubMed]
  • Gustafson L. Frontal lobe degeneration of non-Alzheimer type. II. Clinical picture and differential diagnosis. Arch Gerontol Geriatr. 1987 Sep;6(3):209–223. [PubMed]
  • Neary D, Snowden JS, Northen B, Goulding P. Dementia of frontal lobe type. J Neurol Neurosurg Psychiatry. 1988 Mar;51(3):353–361. [PMC free article] [PubMed]
  • Mendez MF, Selwood A, Mastri AR, Frey WH., 2nd Pick's disease versus Alzheimer's disease: a comparison of clinical characteristics. Neurology. 1993 Feb;43(2):289–292. [PubMed]
  • Harper PS. Huntington disease and the abuse of genetics. Am J Hum Genet. 1992 Mar;50(3):460–464. [PubMed]
  • Markel DS, Young AB, Penney JB. At-risk persons' attitudes toward presymptomatic and prenatal testing of Huntington disease in Michigan. Am J Med Genet. 1987 Feb;26(2):295–305. [PubMed]
  • Meissen GJ, Berchek RL. Intended use of predictive testing by those at risk for Huntington disease. Am J Med Genet. 1987 Feb;26(2):283–293. [PubMed]
  • Kessler S, Field T, Worth L, Mosbarger H. Attitudes of persons at risk for Huntington disease toward predictive testing. Am J Med Genet. 1987 Feb;26(2):259–270. [PubMed]
  • Terrenoire G. Huntington's disease and the ethics of genetic prediction. J Med Ethics. 1992 Jun;18(2):79–85. [PMC free article] [PubMed]
  • Huggins M, Bloch M, Kanani S, Quarrell OW, Theilman J, Hedrick A, Dickens B, Lynch A, Hayden M. Ethical and legal dilemmas arising during predictive testing for adult-onset disease: the experience of Huntington disease. Am J Hum Genet. 1990 Jul;47(1):4–12. [PubMed]
  • Hayden MR. Predictive testing for Huntington disease: are we ready for widespread community implementation? Am J Med Genet. 1991 Sep 15;40(4):515–517. [PubMed]
  • van der Steenstraten IM, Tibben A, Roos RA, van de Kamp JJ, Niermeijer MF. Predictive testing for Huntington disease: nonparticipants compared with participants in the Dutch program. Am J Hum Genet. 1994 Oct;55(4):618–625. [PubMed]
  • Lannfelt L, Axelman K, Lilius L, Basun H. Genetic counseling in a Swedish Alzheimer family with amyloid precursor protein mutation. Am J Hum Genet. 1995 Jan;56(1):332–335. [PubMed]
  • Lennox A, Karlinsky H, Meschino W, Buchanan JA, Percy ME, Berg JM. Molecular genetic predictive testing for Alzheimer's disease: deliberations and preliminary recommendations. Alzheimer Dis Assoc Disord. 1994;8(2):126–147. [PubMed]
  • Karlinsky H, Sadovnick AD, Burgess MM, Langlois S, Hayden MR, Berg JM. Issues in molecular genetic testing of individuals with suspected early-onset familial Alzheimer's disease. Alzheimer Dis Assoc Disord. 1994;8(2):116–125. [PubMed]
  • Tibben A, Frets PG, van de Kamp JJ, Niermeijer MF, Vegter-van der Vlis M, Roos RA, van Ommen GJ, Duivenvoorden HJ, Verhage F. Presymptomatic DNA-testing for Huntington disease: pretest attitudes and expectations of applicants and their partners in the Dutch program. Am J Med Genet. 1993 May 1;48(1):10–16. [PubMed]
  • Mac Kay CR. Discussion points to consider in research related to the human genome. Hum Gene Ther. 1993 Aug;4(4):477–495. [PubMed]
  • Wiggins S, Whyte P, Huggins M, Adam S, Theilmann J, Bloch M, Sheps SB, Schechter MT, Hayden MR. The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med. 1992 Nov 12;327(20):1401–1405. [PubMed]
  • Bloch M, Fahy M, Fox S, Hayden MR. Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet. 1989 Feb;32(2):217–224. [PubMed]
  • Meissen GJ, Mastromauro CA, Kiely DK, McNamara DS, Myers RH. Understanding the decision to take the predictive test for Huntington disease. Am J Med Genet. 1991 Jun 15;39(4):404–410. [PubMed]
  • Quaid KA, Brandt J, Faden RR, Folstein SE. Knowledge, attitude, and the decision to be tested for Huntington's disease. Clin Genet. 1989 Dec;36(6):431–438. [PubMed]
  • Kessler S. Forgotten person in the Huntington disease family. Am J Med Genet. 1993 Oct 15;48(3):145–150. [PubMed]
  • Tibben A, Duivenvoorden HJ, Niermeijer MF, Vegter-van der Vlis M, Roos RA, Verhage F. Psychological effects of presymptomatic DNA testing for Huntington's disease in the Dutch program. Psychosom Med. 1994 Nov-Dec;56(6):526–532. [PubMed]
  • Roos RA, Vegter-van der Vlis M, Hermans J, Elshove HM, Moll AC, van de Kamp JJ, Bruyn GW. Age at onset in Huntington's disease: effect of line of inheritance and patient's sex. J Med Genet. 1991 Aug;28(8):515–519. [PMC free article] [PubMed]
  • Schulman JD, Black SH, Handyside A, Nance WE. Preimplantation genetic testing for Huntington disease and certain other dominantly inherited disorders. Clin Genet. 1996 Feb;49(2):57–58. [PubMed]
  • Culliton BJ. Genes and discrimination. Nat Med. 1995 May;1(5):385–385. [PubMed]
  • Martindale B. Huntington's chorea: some psychodynamics seen in those at risk and in the responses of the helping professions. Br J Psychiatry. 1987 Mar;150:319–323. [PubMed]
  • Thies U, Bockel B, Bochdalofsky V. Attitudes of neurologists, psychiatrists, and psychotherapists towards predictive testing for Huntington's disease in Germany. J Med Genet. 1993 Dec;30(12):1023–1027. [PMC free article] [PubMed]
  • Thomassen R, Tibben A, Niermeijer MF, van der Does E, van de Kamp JJ, Verhage F. Attitudes of Dutch general practitioners towards presymptomatic DNA-testing for Huntington disease. Clin Genet. 1993 Feb;43(2):63–68. [PubMed]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group